ABout MDMA

James Allen serves as Sr. Vice President and Chief Financial Officer at B. Braun Medical Inc., where he leads all financial operations for the B. Braun Group of Companies in North America. His responsibilities include executive oversight of the Accounting, Tax, Procurement, Supply Chain, Logistics and IT departments.

Mr. Allen has more than 30 years of finance and management experience across a range of industries and financial disciplines. Prior to joining B. Braun, he served for 6 years as an operating company CFO with Steel Partners, where he led the implementation of multiple successful growth initiatives. In prior roles, Mr. Allen spent 15 years at Johnson & Johnson in a variety of business development and financial leadership roles in the Pharmaceutical and Medical Devices & Diagnostics sectors. He began his career at Amoco Corporation in roles including business development, internal auditing, brand marketing and sales. Mr. Allen holds an MBA from the Kellogg Graduate School of Management at Northwestern University, and a BS in Finance from the University of Maryland. He is a Certified Management Accountant.

Laurent Attias is Head of Corporate Development, Strategy, BD&L and M&A where he leads the development of long-term strategic plans for the Surgical and Vision Care franchises of Alcon and is responsible for the Alcon’s BD&L, M&A, partnerships and alliance activities, a role which he has held since 2015. Since 1994 when Mr. Attias joined Alcon, he has had various roles with increasing responsibility beginning with positions in Alcon’s Sales and Marketing functions and then holding the positions of Vice President, Refractive Sales and Marketing from 2002 to 2007; Vice President/General Manager of Alcon Canada from 2007 to 2009; Vice President, Central & Eastern Europe, Italy and Greece from 2009 to 2010; and President, Europe, Middle East and Africa (“EMEA”) from 2010 to 2012. From 2012 to 2015 as Senior Vice President of Global Commercial Franchises, Mr. Attias lead all commercial execution and product pipeline activities of Alcon’s Surgical, Pharmaceutical and Vision Care franchises.

Mr. Attias holds both a Bachelor of Business Administration in Marketing and a Master of Business Administration from Texas Christian University.

Quentin Blackford has served as a member of our board of directors since September 2023. Mr. Blackford currently serves as the President and Chief Executive Officer at iRhythm Technologies (NASDAQ: IRTC), a leading digital healthcare solutions company. Prior to iRhythm Technologies, Mr. Blackford served at Dexcom, Inc. from 2017 to 2021, first as Chief Financial Officer and then as Chief Operating Officer. Prior to Dexcom, Mr. Blackford served at Nuvasive, Inc. from 2009 to 2017, including as Chief Financial Officer and as Head of Strategy and Corporate Integrity from 2014 to 2017. Prior to 2009, Mr. Blackford served at Zimmer Biomet, Inc. (NYSE: ZBH) in various senior financial leadership positions. Since October 2017, Mr. Blackford also serves as a member of the board of directors of Alphatec Holdings, Inc. (NASDAQ: ATEC), where he serves on the compensation committee and audit committee. Mr. Blackford is a Certified Public Accountant (inactive) and received dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.

Todd J. Brinton, M.D., has been corporate vice president, advanced technology, and chief scientific officer, since 2019. Dr. Brinton has significant experience as a champion of cardiovascular innovation and has a strong patient focus as a tenured practicing clinical cardiologist. He has deep ties to the medical technology community as a founder, board member and advisor to several start-up companies, including his role as physician founder, board member, and chief medical officer of Shockwave Medical, Inc (SWAV). Dr. Brinton began his career as an engineer in the medical technology industry, ultimately becoming a director of clinical research and development, prior to entering medical school. Before joining Edwards, he was a clinical professor of medicine (cardiology) and adjunct professor of bioengineering at the Stanford University School of Medicine. He was an attending interventional cardiologist at both the Stanford University Medical Center and the Palo Alto VA Medical Center. Dr. Brinton also served as the fellowship director at the Stanford Byers Center for Biodesign from 2006 to 2019, where he mentored and directed numerous teams on the development of new technologies. In addition, he served as the co-director for both the graduate and executive education programs at the center during a similar time period. He is currently an Adjunct Professor of Medicine (Cardiology) at Stanford University as well as senior advisor and member of the Board for the Stanford Byers Center for Biodesign. He is extremely active in the American Heart Association serving as the Chair of the 2022 Bay Area Research Roundtable and the 2022 Orange County Heart & Stroke Ball. He currently serves on the AHA national research committee and Board of Directors for the AHA Western region. He also serves on the Board of Directors for the Medical Device Manufacturers Association and advisory boards for the Edwards Lifesciences Foundation Cardiovascular Innovation and Research Center at UC Irvine. Dr. Brinton received his bachelor’s degree from the University of California, San Diego in biomedical engineering, and his medical degree from the Chicago Medical School at Rosalind Franklin University. He completed his internship, residency, and fellowships in cardiology and interventional cardiology at Stanford.

Mike Carrel joined AtriCure as President and Chief Executive Officer in 2012. Under his leadership, the company has consistently grown revenue at more than 20% per year and the employee base has grown from 200 to over 500 today. Additionally, he has established a patient first company culture, in which the company is investing in ground-breaking clinical trials for the treatment of Atrial Fibrillation and Left Atrial Appendage Management. In addition, during his tenure AtriCure has acquired two companies, Estech and nContact, who have brought leading ablation technologies to further AtriCure’s market position worldwide. Mr. Carrel also serves on the boards of Lombard Medical, the Medical Device Manufacturers Association (MDMA), and the American Heart Association Chapter in Minneapolis.

Mr. Carrel previously served as the President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company, from 2008 until 2012. He originally joined Vital Images in January 2005 as Chief Operating Officer and Chief Financial Officer. During his tenure at Vital Images, Mr. Carrel led the company to a leadership position in the healthcare and medical software industry. Under his leadership, the company grew revenue and profitability, increased global market share, expanded its presence to over 90 countries, and raised 100 million dollars in equity financings. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems, now part of Motorola. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from the Wharton School at the University of Pennsylvania.

Andrew I. Chang is President of Carl Zeiss Meditec USA, Inc., Head of Global Sales Ophthalmic Devices, Board Member for MicroOptx, ASCRS Foundation, Ophthalmology Foundation, Cataract Technologies Inc. and founding member of Vanguard Ophthalmology Society.

Andy’s breadth of experience across the ophthalmic industry in diagnostic and surgical devices, as well as pharmaceuticals has made him an exceptional leader in the industry. His understanding of the needs of the clinician and how technology can improve their work has successfully transitioned some of the ophthalmic industry’s most influential companies to the next level in market leadership. Through partnership with doctors from early-stage development to integrating and implementing cutting-edge technologies into daily clinical practice Andy has made significant contributions to the expansion of offerings for ophthalmic and optometric customers worldwide.

Prior to joining ZEISS, Andy was General Manager and Senior Vice President for Bausch + Lomb Surgical where he led the sales, marketing, operations and business development for the US. Previously at Optimedica Corporation / Abbott Medical Optics, Inc., Andy led the marketing and launch of new laser systems and new indications globally. At ISTA Pharmaceutical / Bausch + Lomb, Andy held various marketing, sales and product development roles and led the market introductions of ophthalmic pharmaceuticals.

Ryan joined NEA in 1996, and became a General Partner in 2004.He specializes in healthcare investments in the specialty pharma, medical device and healthcare information technology sectors. Present board memberships include BENU, Carticept Medical, Concentric Medical, ExploraMed III, ForHealth Technologies, Intrinsic Therapeutics, Neotract, PatientKeeper, Simplex Diabetic Supply, Spine Wave, Viacor and Vibrynt. Ryan also co-manages NEA’s investment in TriVascular2.Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Esprit Pharma (acquired by Allergan),FoxHollow Technologies (NASDAQ: FOXH), Provation Medical (acquired by Wolters Kluwer), and Proxima Therapeutics (acquired by Cytyc Corporation), and Ryan co-led NEA’s investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.). Prior to joining NEA, Ryan was with the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco. Previously, he worked in the San Francisco office of Arthur Andersen & Co. Ryan received a BA from Stanford University.

Laura A. Francis has served as our Chief Executive Officer and a Director on our Board since April 2021. As our Chief Financial Officer since May 2015 and Chief Operating Officer since July 2019, Ms. Francis played a fundamental role in bringing the company public in October 2018 and building the operations of the business. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with public and private life science companies, including Auxogyn, now part of Progyny (Nasdaq: PGNY), Promega Corporation, and Bruker Corporation (Nasdaq: BRKR). Earlier in her career, she was an Engagement Manager with McKinsey & Company and Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers. Ms. Francis has been a Director for Shockwave Medical (Nasdaq: SWAV) since January 2019, where she serves as Audit Committee Chair and Compensation Committee Member. She received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.

Gregory A. Fredde is Executive Vice President of Business Development for Merit Medical Systems, Inc. headquartered in South Jordan, Utah. Since joining Merit Medical in 2003, Mr. Fredde has participated in nearly 100 transactions with a total transactional value of nearly $1 billion and contributing over $450 million in annual revenues. These transactions have included equity investments, distribution agreements, asset and stock purchases, and technology transfers.

Mr. Fredde has also led on-site integration teams for Merit’s acquisitions. These responsibilities have included consolidation of facilities, integration of retained employees, termination of previous business agreements, coordination of IT-based systems, and management of and compliance with ancillary agreement including CMAs, TSAs, and distribution agreements.

Mr. Fredde currently represents Merit on six corporate boards of directors in whose companies Merit is an investor.

Merit Medical is Utah’s largest home-grown medical device company with 6,000 worldwide employees in ten manufacturing facilities throughout the world including the United States., Mexico, Ireland, The Netherlands, France, Brazil, Australia, and Singapore. Since its founding in 1987, Merit’s annual revenues are projected to exceed $1 billion in 2019.

Prior to working with Merit, Mr. Fredde was President of the Utah Mining Association from 2001-2003. Mr. Fredde also served as Vice President of the Utah Taxpayers Association and has worked in a variety of local, state, and federal positions including the U.S. Department of State, State of Utah Community and Economic Development, and Ogden City’s Mayor’s Office.

Mr. Fredde graduated from the University of Utah with Bachelor of Science and Master of Arts degrees in Political Science.

Doug Godshall serves as Chairman of the Board of Directors for Saluda Medical and as Executive Chairman for Galvanize Therapeutics. Saluda is developing and commercializing disruptive neuromodulation systems using it’s novel Smartloop™ algorithm. Galvanize designs and develops Pulsed Electric Field Systems to achieve meaningful and lasting outcomes in the fields of oncology and chronic bronchitis. Mr. Godshall most recently served for 7 years as President and CEO of Shockwave Medical until its acquisition by Johnson and Johnson in May of 2024 for $13B. Shockwave developed and commercialized interventional tools to treat calcified structures throughout the cardiovascular system and devices to treat patients suffering from refractory angina. Prior to Shockwave, he served as President and Chief Executive Officer of HeartWare International, Inc., a leader in the LVAD market where he served for 10 years until the company was acquired by Medtronic in August of 2016 for $1.1B. Prior to HeartWare, he held various executive and leadership positions at Boston Scientific, including President of the Vascular Surgery Division, a member of Boston Scientific’s Operating Committee and had previously served as Vice President, Business Development where he was responsible for more than 70 transactions. Mr. Godshall holds an M.B.A. from Northeastern University and a BA in Economics from Lafayette College.

Scott Huennekens is Executive Chairman of Euclid, Inc., Chairman of Envista, Executive Chairman Wondr Medical, Chairman Digma Medical and on the boards of Viewray, Nuvasive, and Kardion. He is the former Chairman, President & CEO of Verb Surgical, Google and J&J’s Surgical Robotics company having left there in early 2019. Previously, Scott was the President & CEO of Volcano from 2002 to 2015 and lead the company’s growth from a start up to sales over $400 million in revenue and a market cap that approached $2B prior to its sale to Philips in February 2015. He was the President & CEO of Digirad Corporation, a medical imaging company, Digirad grew from a pre-revenue start up when Scott joined in 1997 to a public company in 2004. He has served on the boards of numerous other medical device companies and currently serves as the Past Chairman for the Medical Device Manufacturers Association (MDMA). Scott received a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard Business School.

Liam J. Kelly is the Chairman, President and CEO of Teleflex. Mr. Kelly became Chairman of the Teleflex Board on May 1, 2020 and has served as the company’s President and Chief Executive Officer since January 1, 2018. He joined Teleflex in April 2009 and held a variety of roles, including President of EMEA. He was then promoted to the position of Executive Vice President and President, International in June 2012. In April 2014, Mr. Kelly was appointed Executive Vice President and President, Americas. In April 2015, Mr. Kelly was named Executive Vice President and Chief Operating Officer. From May 2016 to December 2017, he served as President and Chief Operating Officer.

Prior to joining Teleflex, Mr. Kelly worked at Hill-Rom where he held management and senior leadership positions from 1999 to 2009. He was the Vice President of International Marketing and Product Development and previously had been Managing Director of their UK & Ireland businesses.

Mr. Kelly was named to the Colfax Corporation Board of Directors on January 1, 2020. Mr. Kelly also serves on their Governance Committee.

Mr. Kelly holds a Bachelor of Business Studies from University of Limerick.

Jennifer Kerr is the President of Cook Research, Inc. In her role, Jennifer has executive oversight of product development, testing, clinical studies, medical/scientific writing, and regulatory submissions for devices, pharmaceuticals and cell-based therapies as requested by Cook. Additionally, Jennifer oversees and directs the alignment between Cook Research and the needs of the Cook Strategic Business Units (SBUs) and Cook entities. Jennifer provides leadership by identifying and communicating Cook needs and priorities and working to assure customer expectations are met. In her role she is responsible for scientific and clinical leadership in the conduct of global clinical studies on behalf of the Cook organization and for managing resources required to coordinate the overall function of the company to ensure that deadlines are met.

Jennifer received a BSE in Interdisciplinary Engineering and a MS in Veterinary Physiology and Pharmacology from Purdue University.

Justin Klein, MD, JD is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin was previously a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently or previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical, and VytronUS. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.

Mr. Kohut is Senior Vice President, Commercial Strategy & Development for RoundTable and joined the Firm in January 2017. He works closely with the management teams of RoundTable’s portfolio companies on the development and execution of sales strategies to help ensure best in market practices and the highest of performance. Mr. Kohut also serves as an industry contact for RoundTable’s portfolio company executives. Mr. Kohut has nearly 30 years of healthcare industry experience, primarily in commercial leadership roles. Mr. Kohut is currently serving as interim CEO of Healthcare Components Group, a RoundTable Healthcare Partner’s portfolio company, since August 7, 2023.

Prior to joining the Firm, Mr. Kohut held progressive leadership roles throughout his 20 years with Cardinal including leading Cardinal Health’s international efforts and launching Cardinal Health’s re-entry into the international markets for its medical segment. He later led Cardinal Health’s Hospital Sales & Services efforts as the Senior Vice President of Cardinal’s Medical Segment.

PROFESSIONAL EXPERIENCE

– Senior Vice President; RoundTable Healthcare Partners; Jan 2017- Present
– Interim CEO, Healthcare Components Group; August 7, 2023- Present
– Senior Vice President, Hospital Sales & Services; Cardinal Health; 2014 – 2016
– Group Vice President, Global Sales & Channel Management; Cardinal Health; 2012 – 2014
– National Vice President Sales, Medical & Surgical Products; Cardinal Health; 2006 – 2012
– Cardinal Health, Various Senior Sales Roles; 1997- 2006
– Medline Industries; Prior 1997

Mr. Kohut is currently a Member of the Board of Directors of EHOB, Inc (a RoundTable Healthcare Partner’s portfolio company) & Revere Electric. Mr. Kohut also served as a former Member of the Board of Trustees of The Association of periOperative Registered Nurses (AORN), Health Industry Distributors Assoc. (HIDA), and The Bowling Green University Alumni Board of Directors.

ACADEMIC BACKGROUND

– Bachelor’s degree in Political Science/International Relations, Bowling Green University, 1994

Paul LaViolette joined SV Health Investors in 2009 as a Venture Partner and in 2011 was made a Partner. Paul was promoted to Managing Partner & COO in 2014 and heads our medical device investments. Paul built and ran medical device businesses for 29 years. Before joining SV, he most recently was Chief Operating Officer at Boston Scientific (BSC), an $8 billion medical device leader. During his 15 years at BSC, Paul served as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. During his tenure, the company grew revenue over 20 times. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Previously, Paul held marketing and general management positions at CR Bard and various marketing roles at Kendall (Medtronic).

Paul served as Chairman of the Medical Device Manufacturing Association and as Vice Chairman of the Innovation Advisory Board for the Partners Health System. Paul also served on the board of Advamed for 10 years and is a routine speaker at industry meetings.

Paul received his BA in Psychology from Fairfield University and his MBA from Boston College.

Frank Leonard has served as Executive Vice President and President, Novocure Oncology, since January 2024. He is responsible for Novocure’s global commercial business operations.

Mr. Leonard most recently served as President, CNS Cancers U.S., overseeing U.S. business operations for our glioblastoma (GBM) indications.

Mr. Leonard previously served as Chief Development Officer from Sept. 2020 to Sept. 2022. In this role, he was responsible for engineering, product development, business development and the overall strategic and operational leadership of Novocure’s innovation platforms.

Mr. Leonard joined Novocure in 2010 to help prepare the company for the commercial launch of Optune®, now called Optune Gio®. In prior roles, Mr. Leonard established Novocure’s health policy and business development groups, and additionally led various finance functions.

Mr. Leonard has served as a director of the Medical Device Manufacturers Association (MDMA) since 2023. Prior to joining Novocure, he was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.

George A. Leondis is President & CEO of Argon Medical Devices, Inc. He joined the company in July 2009, and has global responsibility for all business operations and functions. He has over 20 years of experience in the medical device industry.

Prior to joining Argon, Mr. Leondis most recently served as General Manager and Corporate Vice President for Angiotech Interventional, a subsidiary of Angiotech Pharmaceuticals, Inc., which manufactured and marketed disposable vascular and non-vascular devices for use in Interventional Radiology, Interventional Cardiology and Vascular Surgery.

After various sales and management roles at companies including Orascoptic Research and St. Jude Medical, Mr. Leondis was hired by InterV/Medical Device Technologies, Inc., which became part of American Medical Instruments Holdings, Inc., a RoundTable Healthcare Partners portfolio company, in 1998.

He was promoted through various positions including Region Manager, Director of Global Marketing, Vice President of Sales, and Sr. Vice President of Sales and Marketing, prior to the company’s sale to Angiotech.

Mr. Leondis holds a Bachelor’s degree from Rutgers University.

James V. (Jim) Mazzo is Executive Chair of Neurotech, a private clinical stage biotech company focused on developing transformative therapies for chronic eye diseases.

Mazzo is an Advisor for Anivive, Bain, CVC Private Equity, Visus, and Zeiss. He sits on the Boards of Emmecell, Iantrek, Pulse Medica, Remonihealth and is the Executive Chair of Trukera and Centricity Vision.

He serves as President of the Ophthalmology Foundation and Board Chair of the Gavin Hebert Eye Institute. Mazzo is on the Advisory Boards of the AAO Foundation, the AGS Foundation, NASA’s Mission to Mars Committee, is an Officer in the Order of St. John, and a Board Member of the Anaheim Ducks Foundation. Mazzo is one of the ophthalmic industry’s best known and most respected business leaders with more than 40 years of proven experience. His global reputation for building and running world-class organizations is based on twenty-two years of leading Allergan’s North American and European eye care organizations; Chairman, President and CEO of Advanced Medical Optics (AMO); EVP of Abbott’s global ophthalmology business; Executive Chair and CEO of AcuFocus; Global President of Ophthalmic Devices for Carl Zeiss Meditec; and President, CEO and Member of the Board for Avellino.

Additionally, he is the Founder and Past Chair of Octane, a member of the International Intraocular Implant Club (lllC) and Executive Committee Board Member with the Medical Device Manufacturers Association (MDMA).

His accomplishments and contributions to the healthcare industry, business and educational communities include serving as Board Chair for AdvaMed, member of the University of California at Irvine Foundation, Vice Chair Trustee with Chapman University, Richard Nixon Foundation Board Member, and years of dedicated experience in the medical device industry including cardiology, dermatology, orthopedics, and ophthalmology. Mazzo’s accolades include recognition as a multi-time Top 100 Innovator in Ophthalmology, and one of Orange County’s Top 50 Executives. In 2023 he received the Ellis Island Medal of Honor, the Lindstrom Leadership Award, and the Orange County Eye Project Lifetime Achievement Award.

Jim has over 23 years of investment and acquisition experience, the vast majority of which was focused on the health care sector. Prior to founding Patient Square Capital in 2020, he spent over 21 years at KKR, initially joining in 1996. He helped establish the firm’s health care industry group in 2001 and subsequently was Head of the Americas Heath Care Team for over 10 years. In that role, he managed a team of over 20 dedicated health care professionals overseeing five different health-care-related investment strategies including private and growth equity. He was a member of the Americas Private Equity Investment Committee beginning in 2013 and was Chairman of both the Health Care Strategic Growth and Health Care Royalty & Income Investment Committees.

Jim currently serves on the Boards of Directors of BridgeBio and PRA Health Sciences (lead independent director). He previously served on the Boards of Directors of Ajax Health, Alliance Imaging, Arbor Pharmaceuticals, BrightSpring Health Services, Covenant Surgical Partners, EchoNous, Entellus Medical, Envision Healthcare, Global Medical Response, HCA, Heartland Dental, Jazz Pharmaceuticals, Lake Region Medical, and Spirox.

Prior to KKR, Jim worked at Donaldson, Lufkin & Jenrette and was involved in a broad range of merchant banking, M&A, debt, equity and restructuring transactions.

Mr. Momtazee holds a B.A. from Stanford University and an M.B.A. from Stanford’s Graduate School of Business.

Mr. Packer is a Board Member of MDMA (Medical Device Manufacturers Association), a national trade association based in Washington, D.C. that advocates for entrepreneurial medical technology companies and is a Board Member of Bruker BioSciences Corporation,a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.Mr. Packer is past Chairperson of MassMEDIC, the industry council for Medical Devices in Massachusetts.

Mr. Packer also served on the Steering Committee for the Massachusetts Life Sciences Initiative, and is a Board Member of the Massachusetts Medical Device Development Center, a University of Massachusetts initiative to incubate medical device companies. Mr. Packer has served as a Board Member for both a public company, as well as numerous private, early stage ventures. In 2006 he was awarded the designation of High Tech All-Star by the Massachusetts Technology Council. He has been recognized by both Forbes and Fortune magazines as a leader of one of the fastest growing small companies in the U.S. In May, 2010, he was named an Ernst & Young Entrepreneur of the Year, 2010 New England finalist.

Walt Rosebrough has been president and chief executive officer of STERIS and a member of its Board of Directors since October 1, 2007. STERIS is a leading provider of infection prevention and procedural products and services, focused primarily on healthcare, pharmaceutical and medical device companies.

He has held leadership positions in most major business functions, including product and business development, manufacturing, finance, and marketing. He has led ventures ranging in scale from start-up operations to multi-billion dollar, multinational businesses with thousands of employees.

Mr. Rosebrough has been an executive in the healthcare industry over 30 years, and CEO for over 25 years. He served as CEO of Support Systems International (SSI), a leading provider of equipment and services to relieve complications of immobility. After the merger of SSI and Hill-Rom, he was named CEO of Hill-Rom, a global leader in patient support systems, therapeutic products, and workflow information technology.

Mr. Rosebrough currently serves on the board of AdvaMed, Health Insights, Rock and Roll Hall of Fame + Museum, and Coastal Hydraulics, Inc. He is a member of the CCI Healthcare Executive Forum, a healthcare roundtable, and Chief Executives Organization. He has served on the boards of Joerns Corporation, The Center for Nursing Leadership, Spalding University and Margaret Mary Hospital.

Mr. Rosebrough holds a bachelor’s degree in Industrial Engineering from Kettering University and an MBA from Stanford University where he was a GM Fellow and Arjay Miller Scholar.

President and CEO of Hyperfine, Inc. Thirty years of experience in commercial and leadership positions in the medical technology industry. Previously, President and CEO of AEGEA Medical, President and CEO of Cardiokinetix, and President and CEO of Concentric Medical, Inc. Complutense University of Madrid MA in Languages. Thunderbird School of International Management Master’s Degree in International Management.

Meghan Scanlon is our senior vice president and president, Urology and Pelvic Health, a position she has held since February 2020. In this role, she is responsible for developing and bringing to market innovative, industry-leading solutions for urological and urogynecological diseases. In addition, Meghan serves as the executive lead for Boston Scientific’s corporate ESG (Environmental, Social & Governance) efforts. Prior to her current role, Meghan served as vice president and commercial general manager for the global Urology and Pelvic Health division. She is a member of the Global Council for Inclusion and serves as the executive sponsor for our PRIDE employee resource group, focused on the LGBTQ+ community. Since joining Boston Scientific in 2014 as vice president, global marketing for Endoscopy, she has progressed through roles of increasing responsibility in Urology and Pelvic Health and Endoscopy, and played a significant role in driving and shaping the global commercial organization structures and portfolio innovation strategies for both businesses. Prior to joining Boston Scientific, Meghan spent nearly 15 years in leadership roles within the Johnson & Johnson medical device business and started her early career as a design engineer at Gillette. She holds a B.S. in Mechanical Engineering from Tufts University and both her M.B.A. and M.S.M.E. from Massachusetts Institute of Technology.

Spencer began his career with Stryker in 1999 with the Endoscopy division. After managing Endoscopy’s Midwest sales region, Spencer was named the Director of Marketing for Stryker Communications in March of 2008. He subsequently became General Manager of the Communications business through 2010 and was responsible for driving adoption and growth throughout the Integrated Operating Room market.

In December 2010, Spencer was named President of Stryker’s Spine division and then President of Instruments in 2015. He has consistently driven globalization efforts and was an important contributor to the design of the Transatlantic Operating Model (TOM). In August of 2018, Spencer became Group President, Neurotechnology, Instruments, Spine (NIS). Within this position, Spencer was responsible for the Instruments division consisting of six business units (Advanced Guidance Technologies, Ear, Nose and Throat, Interventional Spine, Neurosurgical, Orthopaedic Instruments, and Surgical Technologies), Neurovascular, Craniomaxillofacial, and the Spine divisions, as well as the Incubation of Medical Technology function (IMT). Under his leadership, the IMT department focused on the organic development of key technologies, to include Robotics and Enabling Technologies.

In August of 2019, Spencer was named Group President, Orthopaedics and Spine and Interim President, Joint Replacement. In 2021, under Spencer’s leadership the Digital, Robotics, and Enabling Technologies organization was formed; DRE is a centralized division focused on partnering with businesses across the enterprise on the development of digital, robotic, and enabling technology applications and platforms. In 2021, Spencer gained additional global responsibilities for Europe, Eastern Europe, Middle East and Africa (EEMEA), Latin America, and Canada. At this time, Stryker’s enterprise M&A function, inclusive of strategic deal rationale and capital deployment, also shifted under Spencer’s leadership.

Throughout his tenure with Stryker, Spencer has been instrumental in bringing several acquisitions from concept through integration. Most recently, he led the acquisitions of K2M Holdings, Mobius
Imaging/Cardan Robotics, OrthoSensor, and Wright Medical (Stryker’s largest acquisition to date). Additionally, Spencer helped to evaluate breakthrough areas for Stryker, such as Women’s Health, and Ear Nose Throat, and completed key acquisitions in these segments.

Spencer holds an executive leadership position on a number of external committees and boards, focused on social and organizational responsibility.

Spencer holds a Master’s Degree in Business Administration from the University of Nebraska and a Bachelor’s of Science Degree from Miami University.

Chris Sweeney is a partner with Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. He has invested in the healthcare industry for his entire career. Chris was a member of the founding team at Water Street, where he has been instrumental in building a leading group of companies specializing in medical products and diagnostics. Prior to Water Street, Chris was a principal with Cleary & Oxford, a middle-market healthcare investment banking firm. In this role, he represented numerous companies, including Johnson & Johnson, Kimberly-Clark, Medex and B. Braun. Chris currently serves on the boards of Breg and Safeguard Medical. He also is a board member of the Medical Device Manufacturers Association (MDMA). Chris earned a bachelor’s degree in economics and history from Williams College.

Ivan Tornos was appointed President and Chief Executive Officer and a member of the Board of Directors of Zimmer Biomet in August 2023. Mr. Tornos joined Zimmer Biomet in November 2018 as Group President, Orthopedics, and a year later was named Group President, Global Businesses and the Americas. He was appointed as Chief Operating Officer in March 2021 with responsibility for overseeing all global businesses at Zimmer Biomet, as well as leading the global operations, clinical and medical education and global R&D and New Product Development functions. In this role, he had oversight of the Americas and the Europe, Middle East and Africa (EMEA) regions.

Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Gl​obal Urology, Medical and Critical Care Division of Becton, Dickinson and Company. Prior to that, he was with C.R. Bard in positions of increasing responsibility, most recently serving as President, Europe, Middle East and Africa Regions. Before joining C.R. Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging segments of Covidien International. Before that, Mr. Tornos served as International Vice President, Business Development and Strategy with Baxter International Inc. and prior to that, he spent over a decade in leadership assignments around the globe with Johnson & Johnson.

Mr. Tornos is an alumnus of the Harvard Business School, having graduated from the Advanced Management Program and also completed leadership and management programs at the Cox School of Business of Southern Methodist University. He finalized post-MBA work at the Wharton School of the University of Pennsylvania (CPD Marketing/Finance), holds an MBA from the University of Miami School of Business and a BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business. Mr. Tornos currently serves as an independent member of the Board of Directors of global healthcare company PHC Holdings Corporation.

Randel is Abbott’s Senior Vice President, Cardiac Rhythm Management. He was appointed to this role in 2019. He previously served as Vice President, Global Operations, Cardiovascular and Neuromodulation.

Randel joined Abbott in 2012 as Divisional Vice President, Manufacturing Operations. He began his now more than 30-year career in cardiovascular R&D at American Hospital Supply Cardiovascular Group, and subsequently held leadership positions at a variety of companies. These include Vice President, Operations at Edwards Lifesciences; Senior Vice President, Technology and Operations at Vertos Medical, and numerous positions in R&D and operations, including Vice President, Global Manufacturing, at Baxter International.

Randel earned his bachelor of science degree in Mechanical Engineering from California Polytechnic University, San Luis Obispo, California. He also holds a graduate certificate in Biomedical Engineering from University of California, Irvine and a master’s degree in Business Administration from Pepperdine University, Malibu, California.